LibenTech develops the LVP-K® viral vector platform, a proprietary delivery system engineered for enhanced safety and efficiency in gene therapy applications. This platform enables precise delivery of genetic material to target cells, aiming to overcome hurdles in treating intractable diseases like cancer and rare genetic disorders.
Funding
Funding not disclosed
Founders
Product
Problem
Developing effective gene therapies for intractable diseases is hindered by the limitations of current viral vector delivery systems. These systems often lack the necessary safety profile and efficiency for targeted therapeutic delivery, impacting the potential for treating complex genetic disorders.
Solution
LibenTech addresses these challenges by developing the LVP-K® viral vector platform, a proprietary delivery system designed for enhanced safety and efficiency in gene therapy applications. This platform focuses on enabling the precise delivery of genetic material to target cells, aiming to overcome the hurdles in treating a range of intractable diseases. LibenTech's approach centers on advancing gene therapy solutions through its innovative viral vector technology, positioning it as a key enabler for next-generation therapeutics. The company's platform is engineered to facilitate the efficient and safe transfer of therapeutic genes, with the goal of improving patient outcomes for conditions with limited treatment options.
Target Audience
LibenTech targets pharmaceutical companies and biotechnology firms engaged in the development of gene therapies, particularly those focused on oncology and rare genetic diseases.
Features
- LVP-K® viral vector platform engineered for high safety and efficiency in gene delivery.
- Proprietary technology designed to address unmet needs in treating intractable diseases.
- Platform supports the insertion of up to 5 genes and includes a transgenic cassette for protein expression.
- Capable of achieving high titer viral production, exceeding 10¹¹ pfu/ml through cell line adaptation.
- Facilitates the stable and efficient expression of foreign genes, accommodating inserts up to 6kb.
- Designed for cell-specific targeting and potential Blood-Brain Barrier (BBB) penetration.
- Viral replication and propagation occur within the cytoplasm, contributing to a favorable safety profile.
- Exhibits broad efficacy across various cancer types, inducing tumor suppression, cell death, and immune responses.
- Features genetic engineering flexibility with four plasmid DNA MCS sites for enhanced construct design.